News

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

Patients in the integrated and standard care treatment arms reported similar SCL-10 scores indicative of psychological stress and symptom burden, both at baseline and after the completion of DAA treatment.

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

BIOS-ROP study results indicate the bevacizumab biosimilar monotherapy leads to complete ROP regression in almost two-third of the eyes after 24 weeks of treatment.

After studying sweat metabolic changes, investigators noted significant effects in the metabolism of carbohydrates, amino acids, energy metabolism, the urea cycle, and metabolic pathways connected to oxidative stress due to OSA and the severity stage.

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’

This endocrine case report from Brady Pregerson, MD, features a man in his 40s with a history of T1D presenting with waxing and waning right groin and inner thigh pain. Can you determine the proper diagnosis?

The FDA grants the company agreement under a Special Protocol Assessment to evaluate TRS01 ophthalmic solution for the treatment of non-infectious uveitis, including uveitic glaucoma.

Compared to individuals without OSA and regular sleep, individuals with OSA combined with severely irregular sleep had the highest odds of hypertension, according to a new study.

Findings suggest serum C3 may be a viable biomarker for the occurrence and prognosis of IgAN, highlighting the role of the complement system in the disease’s pathogenesis.

During this segment of his interview, Eingun James Song, MD, spoke about upcoming treatments for psoriasis and personalizing care for patients.

Patients ≥ 65 years of age experienced similar rates of remission and adverse events compared to their younger counterparts, with no significant difference in change in renal function observed between the 2 groups.

Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.

Autonomous AI increases diabetic eye exam completion rates in a diverse population of youth with diabetes.

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

Results of the PRECISION trial suggest use of iron-whey-protein microspheres could aid in improving adherence to oral iron therapy as well as staving off adverse GI events.

Data from a new study suggests the Montreal Cognitive Assessment cut points should be lowered for both English and Spanish screenings for more accurate cognitive impairment screenings.

Results of the retrospective study suggested blood pressure, serum IgA, potassium, and segmental glomerulosclerosis may be predictive of the rapid progression of renal endpoints in patients with concurrent IgAN and membranous nephropathy.

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

Screening for liver fibrosis was associated with sustained improvements in alcohol consumption, diet, weight, and exercise in individuals at risk of ALD and MASLD.

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.

A local corticosteroid burst followed by 0.18 mg FAi may be a useful adjuvant for the treatment of noninfectious uveitis, but not sufficient as solo therapy.

Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.

Moderate-to-severe anemia decreased the likelihood of a favorable outcome after mechanical thrombectomy compared with no anemia.

During a 10-year period, estimated access to drugs increased among Polish patients with rheumatic and musculoskeletal diseases.

The novel topical dry eye disease candidate achieved a statistically significant ≥10-mm increase in unanesthetized Schirmer’s score at Day 14.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.